Related Experiment Video
Updated: Apr 30, 2026
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis
Li Zhuang1,2, Awais Ali3, Ling Yang1,2
1Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing 100091, China.
A novel multi-epitope vaccine (MEV) candidate, ZL12138L, has been designed for tuberculosis (TB) prevention. Computational analyses indicate ZL12138L demonstrates high immunogenicity, broad population coverage, and potential for robust immune activation against TB.
Area of Science:
- Vaccinology
- Computational Biology
- Immunoinformatics
Background:
- Tuberculosis (TB) poses a significant global health threat.
- The current Bacillus Calmette-Guérin vaccine offers limited protection against adult pulmonary TB.
- Development of novel vaccines with enhanced efficacy is crucial.
Purpose of the Study:
- To design and computationally evaluate a novel multi-epitope vaccine (MEV) for tuberculosis (TB).
- To assess the immunogenicity, stability, and potential efficacy of the designed MEV using bioinformatics and immunoinformatics approaches.
Main Methods:
- Utilized computer-aided design, artificial intelligence, bioinformatics, and immunoinformatics.
- Constructed a MEV (ZL12138L) incorporating T-cell and B-cell epitopes, TLR agonists, and helper peptides.
- Performed comprehensive analyses including physicochemical properties, structural integrity, immunogenicity, molecular dynamics, and molecular docking with TLRs.
Main Results:
- The designed MEV, ZL12138L, demonstrated high predicted immunogenicity (score 4.14) and antigenicity (score 0.88).
- ZL12138L exhibited excellent population coverage for HLA class I (92.41%) and class II (90.17%) alleles globally.
- Molecular docking and simulations confirmed favorable binding with TLR-2 and TLR-4, indicating potential for robust innate and adaptive immune activation, including Type 1 T helper cell responses.
Conclusions:
- ZL12138L is a promising candidate for a new tuberculosis vaccine.
- Further experimental validation and optimization are warranted to advance this vaccine candidate.
